Skip to main content

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss ofFunction Mutations

Clinical Trial Grant
Duke Scholars

Administered By

Dermatology

Awarded By

Endeavor BioMedicines, Inc.

Start Date

May 8, 2023

End Date

June 1, 2026
 

Administered By

Dermatology

Awarded By

Endeavor BioMedicines, Inc.

Start Date

May 8, 2023

End Date

June 1, 2026